scholarly journals Clear Cell Carcinoma of the Abdominal Wall as a Rare Complication of General Obstetric and Gynecologic Surgeries: 15 Years of Experience at a Large Academic Institution

Author(s):  
Yen-Ling Lai ◽  
Heng-Cheng Hsu ◽  
Kuan-Ting Kuo ◽  
Yu-Li Chen ◽  
Chi-An Chen ◽  
...  

The objective of this article was to report the clinicopathological characteristics, treatment modalities, and outcomes of patients with clear cell carcinoma (CCC) of the abdominal wall. Medical records of six patients diagnosed with CCC of the abdominal wall between May 2003 and May 2018 at the National Taiwan University Hospital were reviewed. All patients had prior obstetric or gynecologic surgeries. The primary clinical presentation was enlarging abdominal masses at previous surgical scars. Four patients underwent initial/primary surgeries with/without adjuvant chemotherapy. One patient received neoadjuvant chemotherapy followed by surgical intervention and adjuvant chemotherapy, the other received chemotherapy and sequential radiotherapy without any surgical intervention. Two of four patients undergoing initial/primary surgeries had disease recurrence and the remaining two cases without initial surgery experienced disease progression during primary treatment. Inguinal lymph nodes were the most frequent sites of recurrence. In conclusion, previous obstetric or gynecologic surgery can be a risk factor for CCC of the abdominal wall. Complete resection of abdominal wall tumor and suspected intra-abdominal lesions with hysterectomy and bilateral inguinal lymph nodes dissection may be the primary treatment. Adjuvant chemotherapy would be considered for potential benefits. For patients without bilateral inguinal lymph nodes dissection, careful inguinal lymph node palpation during postoperative surveillance is necessary. More cases are still needed to elucidate the clinical management of this disease.

2020 ◽  
Vol 27 (6) ◽  
pp. 1230-1231
Author(s):  
Sadikah Behbehani ◽  
Paul Magtibay ◽  
Longwen Chen ◽  
Megan Wasson

In Vivo ◽  
2020 ◽  
Vol 34 (4) ◽  
pp. 2147-2152
Author(s):  
LUCA GIANNELLA ◽  
MATTEO SERRI ◽  
ELENA MACCARONI ◽  
JACOPO DI GIUSEPPE ◽  
GIOVANNI DELLI CARPINI ◽  
...  

2012 ◽  
Vol 22 (7) ◽  
pp. 1143-1149 ◽  
Author(s):  
Mika Mizuno ◽  
Hiroaki Kajiyama ◽  
Kiyosumi Shibata ◽  
Kimio Mizuno ◽  
Osamu Yamamuro ◽  
...  

BackgroundIt is controversial whether patients with stage I ovarian clear cell carcinoma (CCC) benefit from postoperative chemotherapy. This study was designed to evaluate the postoperative outcomes associated with the inclusion or exclusion of adjuvant therapy in these patients.MethodsA total of 185 patients who were treated for stage I CCC between 1991 and 2007 were retrospectively evaluated. All of the patients had received comprehensive surgical staging, and their condition had been diagnosed by a central pathological review system. Only one patient with stage IB was excluded from this study.ResultsMedian follow-up time was 62 months (range 7–191 months). Median age was 52 years (30–75 years). There were 41, 93, and 50 patients in stage IA, intraoperative capsule ruptured IC (rupture-IC), and all other-IC groups, respectively. The 5-year recurrence-free survival rates for the substage were 97.6%, 87.8%, and 70.4% (P < 0.001), respectively. Among 134 patients consisting of those in the stage IA and rupture-IC groups, 91 patients received adjuvant chemotherapy (AC) and 43 patients did not (non-AC). There was no significant survival difference in each substage group between the non-AC and AC groups in 5-year recurrence-free survival rate (stage IA, 100% vs 93.8%; rupture-IC, 94.1% vs 86.6%). Multivariate analysis demonstrated that there was no significant prognostic factor for both recurrence and survival among the IA and rupture-IC groups. Postoperative therapy, regimen, and chemotherapy cycles were not significantly affected.ConclusionsThis study indicates that adjuvant chemotherapy does not contribute to the improving prognosis of stage IA ovarian CCC. Whereas the histological type is CCC, the routine adjuvant chemotherapy after comprehensive surgical staging may be unnecessary for patients with at least stage IA.


Medicine ◽  
2017 ◽  
Vol 96 (1) ◽  
pp. e5720 ◽  
Author(s):  
Guoyang Zheng ◽  
Hanzhong Li ◽  
Ji Li ◽  
Xuebin Zhang ◽  
Yushi Zhang ◽  
...  

2018 ◽  
Vol 136 (6) ◽  
pp. 586-590 ◽  
Author(s):  
João Kleber de Almeida Gentile ◽  
Renato Migliore ◽  
Fábio Jorge Neubaner Kistenmacker ◽  
Marcio Menezes de Oliveira ◽  
Rodrigo Biscuola Garcia ◽  
...  

2008 ◽  
Vol 90 (4) ◽  
pp. 1197.e13-1197.e16 ◽  
Author(s):  
Anne Sophie Bats ◽  
Yaelle Zafrani ◽  
Patricia Pautier ◽  
Pierre Duvillard ◽  
Philippe Morice

Sign in / Sign up

Export Citation Format

Share Document